GlaxoSmithKline (NYSE:GSK) announced Monday it plans to purchase 10 million shares of Theravance Inc (NASDAQ:THVRX). for $21.29 a share, an estimates $213 million.GlaxoSmithKline (NYSE:GSK) has potential upside of 14.8% based on a current price of $44.91 and an average consensus analyst price target of $51.56.GlaxoSmithKline is currently below its 50-day moving average (MA) of $44.91 and should find support at its 200-day MA of $43.64.In the last five trading sessions, the 50-day MA has remained constant while the 200-day MA has risen 0.19%.
